Qing Yuan

Qingyuan Pharmaceutical is an AI-driven biotechnology company specializing in the de novo design of small molecule therapeutics. Founded in 2019 and based in Beijing, the company leverages deep reinforcement learning and advanced drug-target interaction (DTA) models to accelerate the discovery of high-affinity candidates for validated oncological and immunological targets. Their platform integrates physicochemical property optimization with synthetic accessibility filters to streamline the transition from computational design to preclinical validation. Qingyuan's current research focus includes precision therapies for triple-negative breast cancer and hepatocellular carcinoma, targeting key signaling nodes such as EGFR, PARP, and JAK1.